Trial reportInternational urology and nephrology2026
Evaluation of the effect of fluoxetine on depression and anxiety levels in hemodialysis patients with major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial.
Trial report in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Letter to the editor: fluoxetine in hemodialysis: methodological limitations and future directions.International urology and nephrology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
purposeTo investigate the effects of fluoxetine on the levels of depression and anxiety in hemodialysis patients.
methodsIn this 8-week randomized double-blind placebo-controlled study, chronic hemodialysis patients who were 18 to 80 years old were assigned to receive a placebo or fluoxetine capsule. Of the 295 screened patients, 54 were diagnosed with major depressive disorder, and 31 were assigned into the fluoxetine or placebo group. Finally, 19 patients completed the trial. The severity of depression and anxiety were assessed biweekly via the Beck Depression Inventory-II (BDI-II) and the anxiety subscale of Hospital Anxiety and Depression Scale (HADS-A), respectively. The statistical package for the social sciences software, version 20 was used for data analysis. Generalized estimating equations (marginal model) were used to compare the changes in the BDI-II and HADS-A scores between the two groups.
resultsAt the end of week 8, the BDI-II score in the fluoxetine group was significantly lower than that in the placebo group (β = -19.22, 95% CI -25.62 to -12.51, P < 0.001). However, the score of the HADS-A did not show a significant difference between the two groups (β = -4.24, 95% CI -16.19 to 7.71, P = 0.487). Ten patients reported side effects which were more common in the fluoxetine group.
conclusionsCompared with placebo, fluoxetine significantly decreased the depression severity. However, this study did not show a significant effect of fluoxetine on the severity of anxiety. Larger, long-term studies are warranted to validate these findings.
trial registrationThe study protocol was registered on IRCT.ir (registration number: IRCT20220422054611N1) ( https://irct.behdasht.gov.ir/search/result?query=IRCT20220422054611N1 ), Registration date: 2022-05-27.
Indexed as
Identifiers
40813551What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.